BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental exertion for Palynziq (pegvaliase-pqpz), a attraction for phenylketonuria (PKU) successful adolescents aged 12 and older.

The FDA approved BioMarin’s supplemental Biologics License Application for Palynziq, making it the lone enzyme substitution therapy approved for PKU absorption successful pediatric patients aged 12 and older.

Phenylketonuria is simply a uncommon inherited upset that causes an amino acerb called phenylalanine (phe) to physique up successful the body.

The support is based connected the results from the Phase 3 PEGASUS study, which demonstrated statistically important reductions successful humor phenylalanine levels compared to fare alone.

Don't Miss:

• Explore the Fire-Safe Energy Storage Company With $185M successful Contracted Revenue

• Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In astatine $0.85/Share

Individuals successful the Palynziq limb showed a important mean simplification from baseline successful humor Phe levels astatine Week 72 compared to those successful the diet-only arm.

The institution is besides pursuing support from the European Medicines Agency to grow attraction options for adolescents successful the EU.

The banal is presently trading 4.5% beneath its 20-day elemental moving mean (SMA) and 8.2% beneath its 100-day SMA, indicating immoderate short-term weakness. Over the past 12 months, shares person decreased by astir 19%, and they are presently positioned person to their 52-week lows than highs, reflecting a challenging marketplace environment.

Trending: Own the Characters, Not Just the Content: Inside a Fast-Growing Pre-IPO IP Company

The RSI is astatine 50.00, suggesting a neutral position, portion the MACD is astatine -0.10, beneath its awesome enactment astatine 0.05, indicating bearish unit connected the stock. The operation of neutral RSI and bearish MACD suggests mixed momentum.

• Key Resistance: $73.50

• Key Support: $50.00

Analyst Consensus & Recent Actions: The banal carries a Buy Rating with an mean terms people of $88.80. Recent expert moves include:

• Canaccord Genuity: Buy (Raises Target to $104.00) (Feb. 26)

• Bernstein: Outperform (Raises Target to $94.00) (Feb. 25)

• Guggenheim: Buy (Lowers Target to $86.00) (Feb. 25)

Read Next: 

• 1.5 Million Users Are Already Working Inside This AI Platform — Investors Can Still Get In

• Blue-chip creation has historically outpaced the S&P 500 since 1995, and fractional investing is present opening this organization plus people to mundane investors.

Photo by Tada Images via Shutterstock